Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNT (CapeOX + IMRT) for High-Risk Rectal Cancer
NCT02864849Phase 2Completed
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Aug 2016
- Primary completion
- Jun 2019
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and oxaliplatin in rectal cancer, sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Major adverse events at 3 years. Started Aug 2016; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT02864849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02864849.